Reuters logo
BRIEF-Cellectar Biosciences provides phase I trial update of CLR 131
February 27, 2017 / 1:37 PM / 10 months ago

BRIEF-Cellectar Biosciences provides phase I trial update of CLR 131

Feb 27 (Reuters) - Cellectar Biosciences Inc

* Cellectar Biosciences provides phase I trial update of CLR 131 in multiple myeloma: median progression-free survival extends to 133 days, median overall survival reaches 17.7 months

* Cellectar Biosciences Inc - data from cohort 3 show that 25 mci/m(2) dose was safe and well tolerated

* Cellectar Biosciences Inc - based on these results, look forward to providing full cohort 3 data update and imminent initiation of phase II clinical trial Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below